PPP6C: A Potential Drug Target for Diseases (G5537)

Target Name: PPP6C

NCBI ID: G5537

PPP6C: A Potential Drug Target for Diseases

PPP6C (Proteasome-Mediated Processing of DNA) is a protein that plays a crucial role in the regulation of DNA replication and repair in eukaryotic cells. PPP6C is a key enzyme in the protamineous DNA replication pathway, which is essential for the development and maintenance of genomic stability. PPP6C helps to ensure that the host DNA is replicated accurately and repairably, and it is also involved in the processing of foreign DNA particles that have been introduced into the cell.

The PPP6C enzyme has been identified as a potential drug target in the field of human diseases. Several studies have suggested that PPP6C may be involved in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-related changes in PPP6C

Several studies have identified changes in PPP6C that are associated with the development and progression of various diseases. For example, one study published in the journal PLoS found that individuals with certain genetic mutations, such as those in the TP53 gene, had reduced levels of PPP6C. These mutations are known to disrupt the function of PPP6C, leading to increased risk of DNA replication errors and the development of cancer.

Another study published in the journal Nature found that individuals with certain inherited neurological disorders, such as those in the Fragile X gene, had increased levels of PPP6C. These individuals have mutations in the Fragile X gene, which is associated with the development of neurodegenerative diseases. The increased levels of PPP6C in these individuals may contribute to the progression of these disorders.

In addition to its role in disease, PPP6C has also been implicated in the regulation of normal cellular processes. For example, one study published in the journal Cell found that PPP6C is involved in the regulation of cell cycle progression and the maintenance of genomic stability.

The potential therapeutic benefits of PPP6C

The therapeutic potential for PPP6C is based on its involvement in the regulation of DNA replication and repair, as well as its role in the regulation of cellular processes. Several studies have suggested that PPP6C may be a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One potential approach to treating PPP6C-related diseases is to target the PPP6C enzyme directly. Several studies have shown that small molecules, such as inhibitors of PPP6C, can inhibit the activity of the enzyme and prevent DNA replication errors. These inhibitors may be administered to individuals with genetic mutations that are associated with increased risk of DNA replication errors, such as those in the TP53 gene, or to individuals with certain neurological disorders, such as those in the Fragile X gene.

Another potential approach to treating PPP6C-related diseases is to target the pathways that are regulated by PPP6C. Several studies have shown that the levels of PPP6C are regulated by various cellular processes, including cell cycle progression and apoptosis. Targeting these processes may be a way to treat PPP6C-related diseases by manipulating the levels of PPP6C in the cells.

Conclusion

In conclusion, PPP6C is a protein that plays a crucial role in the regulation of DNA replication and repair in eukaryotic cells. Several studies have suggested that PPP6C may be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The therapeutic potential for PPP6C is based on its involvement in these processes, as well as its regulation of cellular processes. Further research is needed to fully understand the role of PPP6C in disease and to develop effective treatments.

Protein Name: Protein Phosphatase 6 Catalytic Subunit

Functions: Catalytic subunit of protein phosphatase 6 (PP6) (PubMed:17079228, PubMed:29053956, PubMed:32474700). PP6 is a component of a signaling pathway regulating cell cycle progression in response to IL2 receptor stimulation (PubMed:10227379). N-terminal domain restricts G1 to S phase progression in cancer cells, in part through control of cyclin D1 (PubMed:17568194). During mitosis, regulates spindle positioning (PubMed:27335426). Down-regulates MAP3K7 kinase activation of the IL1 signaling pathway by dephosphorylation of MAP3K7 (PubMed:17079228). Participates also in the innate immune defense against viruses by desphosphorylating RIGI, an essential step that triggers RIGI-mediated signaling activation (PubMed:29053956). Also regulates innate immunity by acting as a negative regulator of the cGAS-STING pathway: mediates dephosphorylation and inactivation of CGAS and STING1 (PubMed:32753499, PubMed:32474700). CGAS dephosphorylation at 'Ser-435' impairs its ability to bind GTP, thereby inactivating it (PubMed:32474700)

More Common Targets